MedTrace Logo

Efficacy of Beraprost in Lowering Pulmonary Arterial Pressure in Children

NCT03431649 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-02-13

No results posted yet for this study

Summary

To analyze the efficacy of beraprost and sildenafil for treatment of pulmonary hypertension in children with left to right shunt.

analyze the efficacy and side effects.

Conditions

  • Pediatric Pulmonary Hypertension

Interventions

DRUG

Beraprost Sodium

1 mcg /kgbw daily, divided in three dosages orally for 12 weeks

DRUG

Sildenafil Citrate

0.4 mg/kgbw each time, 4 times in a day orally for 12 weeks

Sponsors & Collaborators

  • Dr. Soetomo General Hospital

    lead OTHER_GOV

Principal Investigators

  • Mahrus Rachman, MD · Dr. Soetomo General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-01
Primary Completion
2017-07-30
Completion
2017-10-30

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03431649 on ClinicalTrials.gov